| 1 | FDMT4D Molecular Therapeutics, Inc. | 100 | 230195% | -182% | $680M | — |
| 2 | CBIOCRESCENT BIOPHARMA, INC. | 99 | 108340% | -782% | $471M | — |
| 3 | SEPNSepterna, Inc. | 99 | 4175% | -50% | $1.5B | — |
| 4 | XFORX4 Pharmaceuticals, Inc | 98 | 1273% | -226% | $390M | 4 |
| 5 | OVIDOvid Therapeutics Inc. | 97 | 1181% | -339% | $502M | — |
| 6 | GEVOGevo, Inc. | 97 | 849% | -18% | $343M | — |
| 7 | LXRXLEXICON PHARMACEUTICALS, INC. | 96 | 730% | -37% | $1.0B | 4 |
| 8 | CRMDCorMedix Inc. | 95 | 617% | 45% | $686M | 5 |
| 9 | NUVBNuvation Bio Inc. | 94 | 699% | -102% | $2.0B | — |
| 10 | SNDXSyndax Pharmaceuticals Inc | 94 | 628% | -166% | $1.9B | — |
| 11 | ZVRAZEVRA THERAPEUTICS, INC. | 93 | 351% | 78% | $826M | — |
| 12 | AUTLAutolus Therapeutics plc | 92 | 645% | -381% | $421M | 2 |
| 13 | LKFTLakefront Biotherapeutics NV | 92 | 304% | 29% | $2.0B | — |
| 14 | AAPGASCENTAGE PHARMA GROUP INTERNATIONAL | 91 | 311% | -41% | $1.7B | — |
| 15 | XOMAXOMA Royalty Corp | 90 | 56% | 306% | $760M | — |
| 16 | ABUSArbutus Biopharma Corp | 90 | 128% | 84% | $962M | — |
| 17 | ANABANAPTYSBIO, INC | 89 | 157% | -12% | $1.9B | — |
| 18 | ASMBASSEMBLY BIOSCIENCES, INC. | 88 | 154% | -9% | $550M | — |
| 19 | RIGLRIGEL PHARMACEUTICALS INC | 87 | 64% | 122% | $716M | 6 |
| 20 | TBPHTheravance Biopharma, Inc. | 87 | 67% | 104% | $877M | — |
| 21 | PHATPhathom Pharmaceuticals, Inc. | 86 | 217% | -126% | $893M | 4 |
| 22 | GERNGERON CORP | 85 | 139% | -34% | $872M | — |
| 23 | ETONEton Pharmaceuticals, Inc. | 85 | 105% | -6% | $1.0B | 4 |
| 24 | ASPIASP Isotopes Inc. | 84 | 476% | -589% | $709M | 4 |
| 25 | REXREX AMERICAN RESOURCES Corp | 83 | 1% | 110% | $1.5B | 6 |